0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
25 Ansichten3 Seiten
This document discusses challenges in addressing tuberculosis (TB) in children. It notes that historically, children were excluded from TB control programs, which focused only on treating infectious adults. However, there is now growing recognition of TB as a major cause of illness and death in young children from TB-endemic areas. Accurately estimating the disease burden in children is difficult due to challenges in diagnosis and data collection. Key ongoing challenges include improving diagnostic methods, developing child-friendly drug formulations, strengthening collaboration between child healthcare and TB programs, and addressing drug-resistant TB, which threatens traditional control efforts. Better integration of TB and child health services is needed globally to improve care for children in TB-endemic regions.
Originalbeschreibung:
This document is a part of Lancet on the status of Tuberculosis and its impact on child's health
This document discusses challenges in addressing tuberculosis (TB) in children. It notes that historically, children were excluded from TB control programs, which focused only on treating infectious adults. However, there is now growing recognition of TB as a major cause of illness and death in young children from TB-endemic areas. Accurately estimating the disease burden in children is difficult due to challenges in diagnosis and data collection. Key ongoing challenges include improving diagnostic methods, developing child-friendly drug formulations, strengthening collaboration between child healthcare and TB programs, and addressing drug-resistant TB, which threatens traditional control efforts. Better integration of TB and child health services is needed globally to improve care for children in TB-endemic regions.
This document discusses challenges in addressing tuberculosis (TB) in children. It notes that historically, children were excluded from TB control programs, which focused only on treating infectious adults. However, there is now growing recognition of TB as a major cause of illness and death in young children from TB-endemic areas. Accurately estimating the disease burden in children is difficult due to challenges in diagnosis and data collection. Key ongoing challenges include improving diagnostic methods, developing child-friendly drug formulations, strengthening collaboration between child healthcare and TB programs, and addressing drug-resistant TB, which threatens traditional control efforts. Better integration of TB and child health services is needed globally to improve care for children in TB-endemic regions.
www.thelancet.com/respiratory Published online March 24, 2014 http://dx.doi.org/10.1016/S2213-2600(14)70009-8 1
Child health and tuberculosis Historically, children were excluded from programmes for tuberculosis control that focused exclusively on the identication and treatment of infectious adult cases. Tuberculosis was included in the sixth Millennium Development Goal (MDG). This goal focused on major global epidemics, which reinforced the emphasis on epidemic control with little appreciation of the im port- ance of tuberculosis in the context of child survival. This situation is changing. World Tuberculosis Day 2012 was devoted to childhood tuberculosis and there is growing awareness that tuberculosis is a major cause of illness and death in young children in tuberculosis-endemic areas. A recent Save the Children report about preventable deaths in childhood celebrated some impressive achievements, but emphasised that rising inequities will jeopardise the gains. 1 Globally, the deaths in children are increasingly concentrated in the poorest and most disadvantaged groups in society. 1 Tuberculosis is strongly associated with social deprivation, and poverty stricken areas are often pockets of frequent and sustained transmission of Mycobacterium tuberculosis. The contribution of tuberculosis to child mortality requires careful scrutiny in these areas, but accurate data are hard to obtain because of di culties in conrmation of the diagnosis and frequent overlap of clinical presentation with other common causes of child mortality in these settings. Pooled analysis of autopsy studies identied tuberculosis in about 10% of 811 children (with and without HIV infection) who died from respiratory disease in ve African countries. 2 Of the estimated 13 million deaths in children attributed to pneumonia in 2011, most occurred in young children living in tuberculosis-endemic areas, almost half in Africa. 3 Apart from its contribution to pneumonia deaths, tuberculosis can also be the underlying cause in children dying from meningitis, presumed sepsis, HIV/AIDS, or severe malnutrition. 4 The WHO Global Tuberculosis Report 2013 estimates that 530 000 children developed tuberculosis during 2012, resulting in 74 000 deaths in HIV-uninfected children. 5 Estimates are limited by poor case ascertain- ment and incomplete recording and reporting practices. Increasing the visibility of the tuberculosis burden in children requires improved diagnostic methods combined with enhanced surveillance and reporting systems. Until then, mathematical modelling with setting-specic epi demio logical and demographic data and known age-related risks of infection and disease might improve the estimation of disease burden. The table summarises recent progress and key challenges in childhood tuberculosis. Lancet Respir Med 2014 Published Online March 24, 2014 http://dx.doi.org/10.1016/ S2213-2600(14)70009-8 See Editorial Lancet Respir Med 2013: 1: 755 A n d y C r u m p , T D R , W h o / S c i e n c e P h o t o L i b r a r y Progress Challenges Disease burden Updated estimates included in 2013 global tuberculosis report 5 Disease estimates are conservative, and deaths only include children without HIV infection; no information on drug-resistant tuberculosis in children Diagnosis Roll out of Xpert MTB/RIF assay Cartridge cost; restricted availability; no information about isoniazid susceptibility; poor sensitivity in children; no point-of-care test; restricted availability of chest radiography Treatment Drug-susceptible tuberculosis Optimal dose guidance; short-course regimens to be assessed in limited disease Awaiting quality-assured, child-friendly, xed-dose combination preparations Drug-resistant tuberculosis Excellent treatment outcomes in children with drug-resistant tuberculosis; new drugs available; regulatory encouragement to develop child-friendly formulations; and assess safety, tolerability, and pharmacokinetics Few children are treated in existing programmes for the treatment of drug-resistant tuberculosis; many side-eects to consider, especially ototoxicity with injectable drugs Prevention Infection control Greater risk awareness and improved guidelines Poor implementation in most tuberculosis-endemic areas; little awareness of the risk posed to susceptible young children Vaccines Several new candidate vaccines, and well established trial sites No correlate of protection; no protective eect from rst new vaccine tested; di cult to dene clinically relevant trial endpoints Drug-susceptible tuberculosis Pragmatic guidance using simple symptom-based screening; new short-course preventive therapy options Policy-practice gaps remain; safety and tolerability of new short-course options to be established in children Drug-resistant tuberculosis Benet of preventive therapy in susceptible young children after contact with someone who is infectious for multidrug resistance tuberculosis Universal applicability of study ndings is uncertain; di cult to generate high-quality evidence with few children exposed to multidrug-resistance tuberculosis and with variable drug resistance proles Table: Progress and challenges in childhood tuberculosis (updated from Marais and colleagues 6 ) Comment 2 www.thelancet.com/respiratory Published online March 24, 2014 http://dx.doi.org/10.1016/S2213-2600(14)70009-8 Vertical national tuberculosis control programmes (NTPs) can provide improved focus and oversight, but the entry point to diagnosis and care for young children with tuberculosis is usually in the child health- care sector. There is a need for stronger links and collaboration between the child health-care sector and NTPs to provide improved case-detection and management (including at the primary and secondary levels of care), to provide more robust national data of child tuberculosis cases and outcomes, and to undertake gap analysis and operational research to address the wide policy-practice gaps. The need for a more integrated approach to care within the maternal and child health sector is a major theme of the recently launched roadmap for tuberculosis in children. 4
The rising number of cases of drug-resistant tuberculosis threatens traditional control eorts. 7
Descriptions of child contacts with identical resistance proles to adult source cases 8 provide evidence that clinical drug-resistant strains are highly transmissible. True epidemic spread is conrmed with the ndings of molecular epidemiology studies showing high rates of strain clustering of several clones. 9 WHO estimated 450 000 (range 300 000600 000) cases of multidrug- resistant (MDR) tuberculosis in 2012, and less than 20% (77 000) of these received appropriate treatment. 5
Accurate paediatric data are not available, but since children contribute about 10% of the tuberculosis disease burden globally 6 and MDR strains are readily transmitted, about 45 000 paediatric cases might be expected. Surveillance data suggest that the percentages of MDR tuberculosis are similar in children and adults (especially in new adult cases), with high rates of MDR tuberculosis found in children from settings with high HIV prevalence. 10 Unlike adults, treatment outcomes for children with MDR tuberculosis are excellent, with clinical cure rates in excess of 80%. 11 This outcome has been achieved in the absence of child-friendly formulations and pharmacokinetic data to guide dosing in the youngest age groups. For this reason regulatory authorities are now encouraging the testing of tuberculosis drugs in children, to at least ensure the gathering of adequate safety and pharmacokinetic data. 12 Despite routine recommendations to use preventive therapy in young children after exposure to an individual with infectious drug-susceptible tuberculosis, preventive therapy with second-line antituberculosis drugs in child contacts of drug-resistant tuberculosis cases is less well accepted because there are no randomised controlled trials to conrm their eectiveness. 13 With evidence from a pragmatic cohort study in South Africa showing benet, 14 tailored preventive therapy is becoming popular but universal applicability remains a concern. The rise of drug-resistant tuberculosis confronts traditional control eorts with the uncomfortable dilemma of personalised (contextualised) versus programmatic (one size ts all) management, and the involvement of children emphasises the need for greater cooperation and integration of tuberculosis and child health services. Improved integration and optimal-care- delivery models pose a public health challenge globally, 15
but urgent progress is needed to benet children in tuberculosis-endemic areas. *Ben J Marais, H Simon Schaaf, Stephen M Graham Marie Bashir Institute for Infectious Diseases and Biosecurity and Childrens Hospital at Westmead, Sydney Medical School, University of Sydney, Locked Bag 4001, Sydney, NSW 2145, Australia (BJM); Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa (HSS); and Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Childrens Research Institute, Royal Childrens Hospital, Melbourne, VIC, Australia (SMG) ben.marais@health.nsw.gov.au We declare that we have no conicts of interest. 1 Save the Children. Lives on the line: an agenda for ending preventable deaths. 2 Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med 2013; 19: 22937. 3 Liu L, Johnson HL, Cousens S, et al. Global, regional and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 215161. 4 WHO. Roadmap for childhood tuberculosis: towards zero deaths. Geneva: Geneva: World Health Organisation, 2013. WHO/HTM/TB/2013.12 2013 http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137_eng. pdf (accessed Dec 18, 2013). 5 WHO. Global tuberculosis report 2013. Geneva: World Health Organisation, 2013. http://www.who.int/tb/publications/global_report/en/index.html (accessed Dec 18, 2013). 6 Marais BJ, Graham SM, Maeurer M, Zumla A. Progress and challenges in childhood tuberculosis. Lancet Infect Dis 2013; 13: 28789. 7 Abubakar I, Ford N, Cox H, et.al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 52939. 8 Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2014; 58: 38191. 9 Marais BJ, Mlambo CK, Rastogi N, et al. Epidemic spread of multidrug- resistant (MDR) tuberculosis in Johannesburg, South Africa. J Clin Microbiol 2013; 51: 181825. 10 Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42: 70107. Comment www.thelancet.com/respiratory Published online March 24, 2014 http://dx.doi.org/10.1016/S2213-2600(14)70009-8 3 11 Ettehad D, Schaaf HS, Seddon J, et al. Treatment outcomes for children with multi-drug resistant tuberculosis: a systematic review and meta- analysis. Lancet Infect Dis 2012; 12: 44956. 12 Donald PR, Ahmed A, Burman W, et al. Strategies for the clinical evaluation of new antituberculosis agents in children. Int J Tuberc Lung Dis 2013; 17: 79499. 13 van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16: 28896. 14 Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013; 57: 167684. 15 Marais BJ, Lnnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control eorts. Lancet Infect Dis 2013; 13: 43648.